Pathstone Family Office’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pathstone Family Office’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$454K	Buy	6,221 +3,099	+99%	+$248K	﹤0.01%	1084
2023 Q2	$260K	Sell	3,122 -679	-18%	-$56.8K	﹤0.01%	1032
2023 Q1	$290K	Sell	3,801 -20,345	-84%	-$1.69M	﹤0.01%	925
2022 Q4	$976K	Buy	24,146 +13,486	+127%	+$1.09M	0.01%	801
2022 Q3	$845K	Buy	10,660 +7,643	+253%	+$644K	0.01%	828
2022 Q2	$224K	Buy	+3,017	New	+$226K	﹤0.01%	914
2019 Q2	–	Sell	-1,140	Closed	-$103K	–	915
2019 Q1	$103K	Buy	+1,140	New	+$97K	0.01%	229

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Pathstone Family Office's XBI Position: Q3 2023 in Review

Pathstone Family Office increased its State Street SPDR S&P Biotech ETF (XBI) stake by 99% in Q3 2023, buying an estimated $248K and bringing the position to 6,221 shares worth $454K. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Pathstone Family Office first reported a position in XBI in Q1 2019 and has held it in 7 quarters since. The position peaked at $976K in Q4 2022. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Pathstone Family Office held 6,221 shares of State Street SPDR S&P Biotech ETF worth $454K as of Q3 2023.
Pathstone Family Office bought 3,099 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $248K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1084 holding.
Pathstone Family Office first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 7 quarters since.
Pathstone Family Office's State Street SPDR S&P Biotech ETF position peaked at $976K in Q4 2022.
679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.